A REMAINING BURDEN FOR PEOPLE UNABLE TO FULLY BENEFIT FROM VACCINES
761 million cases globally
6.68 million deaths
COVID-19, caused by the SARS-CoV-2 virus, has proven to be a devastating and highly unpredictable disease. Most people infected with the virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, for some, such as frail and immunocompromised patients, SARS-CoV-2 remains a life-threatening pathogen. Their inability to mount a protective immune response also limits the beneficial effect of vaccines, which significantly lower the risk of severe disease in the general population.
The virus evolved surprisingly quickly, resulting in five major variants of concern. The Omicron variant has significantly reduced the effectiveness of the vaccines and has rendered most of the available antibody treatments obsolete.
Our antibodies are highly effective at preventing infection. By binding unique highly conserved epitopes that are difficult to reach for conventional antibodies, they possess a broad specificity.
A bivalent construct that targets an epitope on the S2 region of the SARS-CoV-2 spike protein.
A bivalent construct that targets two epitopes on the S1 region of the SARS-CoV-2 spike protein.
A cocktail of XVR013 and XVR014. It combines multiple modes of action and reduces the risk of immune escape even further by targeting 3 epitopes simultaneously.
Our initial lead candidate for COVID-19, which has completed Phase 1a and Phase 1b studies and showed good pharmacodynamics and efficient GMP manufacturability.
Progressing from research to the clinic in less than 1 year, the compound demonstrates our ability to fast-track drug development using our versatile VHH platform.